IL182879A0 - Polymorphs of sarsapogenin - Google Patents

Polymorphs of sarsapogenin

Info

Publication number
IL182879A0
IL182879A0 IL182879A IL18287907A IL182879A0 IL 182879 A0 IL182879 A0 IL 182879A0 IL 182879 A IL182879 A IL 182879A IL 18287907 A IL18287907 A IL 18287907A IL 182879 A0 IL182879 A0 IL 182879A0
Authority
IL
Israel
Prior art keywords
sarsapogenin
polymorphs
Prior art date
Application number
IL182879A
Other languages
English (en)
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of IL182879A0 publication Critical patent/IL182879A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
IL182879A 2004-11-05 2007-04-30 Polymorphs of sarsapogenin IL182879A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424528A GB0424528D0 (en) 2004-11-05 2004-11-05 Chemical compounds
PCT/GB2005/004266 WO2006048665A2 (en) 2004-11-05 2005-11-04 Polymorphs of sarsapogenin

Publications (1)

Publication Number Publication Date
IL182879A0 true IL182879A0 (en) 2007-08-19

Family

ID=33523268

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182879A IL182879A0 (en) 2004-11-05 2007-04-30 Polymorphs of sarsapogenin

Country Status (17)

Country Link
US (1) US20080194530A1 (ru)
EP (2) EP2479183A3 (ru)
JP (1) JP2008519020A (ru)
KR (1) KR20070089798A (ru)
CN (2) CN101068827B (ru)
AU (1) AU2005300348A1 (ru)
BR (1) BRPI0517648A (ru)
CA (1) CA2584676A1 (ru)
GB (1) GB0424528D0 (ru)
IL (1) IL182879A0 (ru)
MX (1) MX2007005473A (ru)
NO (1) NO20072794L (ru)
RU (1) RU2007119611A (ru)
SG (1) SG158068A1 (ru)
TW (1) TW200635941A (ru)
WO (1) WO2006048665A2 (ru)
ZA (1) ZA200703630B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750510A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CA2805693A1 (en) 2010-07-20 2012-01-26 Phytopharm Plc Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
JP5881525B2 (ja) * 2011-05-16 2016-03-09 ライオン株式会社 サポゲニン安定化組成物の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2306635A (en) * 1940-08-03 1942-12-29 Parke Davis & Co Method for the preparation of steroidal carbinols
US2408827A (en) * 1944-05-15 1946-10-08 Parke Davis & Co Steroidal compounds and methods for obtaining the same
US2774714A (en) * 1952-10-10 1956-12-18 Emanuel B Hershberg Process for the extraction of sapogenins from plant materials
US3019220A (en) * 1958-07-17 1962-01-30 Julian Lab Inc Isolation of sapogenins
US4057543A (en) * 1976-07-01 1977-11-08 G. D. Searle & Co. Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH04230696A (ja) * 1990-12-28 1992-08-19 Sanwa Shiyouyaku Kk 新規なステロイド系化合物および制癌剤
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
KR100217996B1 (ko) * 1996-12-23 1999-09-01 윤종용 프린트 헤드의 노즐 간격 보상 장치 및 방법
CN1198622C (zh) 1998-03-26 2005-04-27 植物药物公共有限公司 用于治疗阿尔茨海默病的甾类皂苷及其衍生物
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
AT409100B (de) 2000-07-24 2002-05-27 Evg Entwicklung Verwert Ges Vorrichtung zum schweissen einer drahtgittermatte
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
ATE424211T1 (de) * 2002-03-27 2009-03-15 Phytopharm Plc Therapeutische verwendung von sapogeninen

Also Published As

Publication number Publication date
JP2008519020A (ja) 2008-06-05
RU2007119611A (ru) 2008-12-10
WO2006048665A2 (en) 2006-05-11
EP2479183A3 (en) 2013-08-28
AU2005300348A1 (en) 2006-05-11
BRPI0517648A (pt) 2008-10-14
TW200635941A (en) 2006-10-16
ZA200703630B (en) 2009-10-28
EP1809650A2 (en) 2007-07-25
SG158068A1 (en) 2010-01-29
EP2479183A2 (en) 2012-07-25
CN101068827B (zh) 2011-06-08
CN102219826A (zh) 2011-10-19
US20080194530A1 (en) 2008-08-14
CN101068827A (zh) 2007-11-07
MX2007005473A (es) 2007-05-24
NO20072794L (no) 2007-07-31
CA2584676A1 (en) 2006-05-11
GB0424528D0 (en) 2004-12-08
KR20070089798A (ko) 2007-09-03
WO2006048665A3 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
PT1802579E (pt) Derivados da 3-arilaminopiridina
GB0823478D0 (en) Method of cementing
IL180742A0 (en) Method of manufacture
PT1778618E (pt) Síntese de trietilenotetraminas
IL181587A0 (en) Production of ??-abeta
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
IL175965A0 (en) Montelukast free acid polymorphs
HK1163672A1 (en) Processes for the preparation of compounds
EP1928489A4 (en) Ghrelin Analogs
PL1931842T3 (pl) Zespół profili
EP1804582A4 (en) POLYMORPH SHAPES OF TADALAFIL
IL175517A0 (en) Processes for preparation of ziprasidone
IL180707A0 (en) Polymorphs of atomoxetine hydrochloride
IL181185A0 (en) Novel polymorphs of azabicyclohexane
EP1711484A4 (en) SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES
GB0410470D0 (en) Pharmaceutical compound and polymorphs thereof
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
EP2057144A4 (en) NEW POLYMORPHIC FROM RIMONABANT
ZA200703630B (en) Polymorphs of sarsapogenin
SI1812422T1 (sl) Kristalna oblika irbesartana
IL187832A0 (en) Methods and intermediates for the preparation of optionally radio- labeled imatinib
IL178184A0 (en) Synthesis of pyrrole-2-carbonitriles
EP1934388A4 (en) METHOD FOR THE DEVELOPMENT OF MEDICAMENTS
IL178683A0 (en) Methods of diminishing co-abuse potenitial
PL369353A1 (pl) Zestaw elementów budowlanych